Specifically, we will increase the number of mice to allow tumor collection at 24 and 48 h following the first and second administration of the inhibitor, enabling us to analyze key protein expression levels, including p53-related proteins (e.g., p21), cell cycle-related proteins (e.g., cdc2), and apoptosis-related proteins (e.g., PARP). Here, CDK1 is linked to neoplasm.